How to Finance a Dermatology Practice Acquisition with an SBA Loan
A step-by-step guide for physician entrepreneurs, medical group buyers, and independent acquirers using SBA 7(a) financing to purchase a dermatology practice generating $1M–$5M in revenue.
Find SBA-Eligible Dermatology Practice BusinessesSBA Overview for Dermatology Practice Acquisitions
SBA 7(a) loans are one of the most practical financing tools for acquiring an independent dermatology practice in the lower middle market. The U.S. Small Business Administration guarantees a portion of these loans, enabling lenders to offer favorable terms — longer repayment periods, lower down payments, and competitive interest rates — that would be difficult to secure through conventional commercial lending alone. For dermatology acquisitions, SBA 7(a) financing is particularly well-suited because the specialty generates strong, recurring cash flows from both insurance-reimbursed medical services and high-margin cash-pay cosmetic procedures such as Botox, fillers, and laser treatments. Lenders view this dual-revenue model favorably when underwriting. However, dermatology deals require careful structuring. Many states enforce corporate practice of medicine (CPOM) laws that prohibit non-physicians from owning a medical practice outright, which means most acquisitions are structured through a Management Services Organization (MSO) framework. SBA lenders with healthcare lending experience understand MSO structures and can underwrite them appropriately. Buyers should select a lender with a proven track record in physician practice acquisitions to avoid delays caused by lender unfamiliarity with CPOM compliance requirements.
Down payment: Most SBA 7(a) lenders require a minimum 10% equity injection for dermatology practice acquisitions, but in practice, buyers should budget for 15–20% down, particularly when the practice carries meaningful key-person risk. If the selling dermatologist generates more than 60–70% of total revenue and is not staying on post-close for a meaningful transition period (typically 12–24 months), lenders will often increase the required down payment to offset that concentration risk. For a dermatology practice selling at a $2.5M purchase price, a 10% down payment equals $250,000, while a 20% requirement brings that figure to $500,000. Buyers frequently combine their equity injection with a seller note — typically 10–15% of the purchase price subordinated to the SBA loan — to reduce the out-of-pocket cash requirement. For example, on a $2.5M deal, a buyer might inject $250,000 in cash (10%), negotiate a $300,000 seller note (12%), and finance the remaining $1,950,000 through the SBA 7(a) loan. Lenders must approve the seller note structure, and it typically must be on full standby for the first 24 months of the SBA loan. Cosmetic revenue mix also influences lender confidence: practices with 30–40% of revenue from high-margin cash-pay aesthetics are generally viewed more favorably and may qualify for lower equity injection requirements due to stronger DSCR (debt service coverage ratio) projections.
SBA Loan Options
SBA 7(a) Standard Loan
10-year repayment for practice acquisitions; variable or fixed interest rates typically at Prime plus 2.25%–2.75%; fully amortizing with no balloon payment
$5,000,000
Best for: Full dermatology practice acquisitions including goodwill, equipment, and working capital — the most commonly used structure for buying an independent dermatology clinic with an established patient base and provider team
SBA 7(a) Small Loan
10-year repayment; streamlined underwriting process with faster approval timelines; similar rate structure to standard 7(a)
$500,000
Best for: Smaller dermatology practice acquisitions or add-on purchases where total deal size is under $500K, such as acquiring a single-provider satellite office or a retiring dermatologist's patient panel and equipment
SBA 504 Loan
10- or 20-year fixed-rate debenture for the CDC portion; typically requires 10% buyer equity injection; structured as two loans — a first lien bank loan and a second lien CDC loan
$5,500,000 (combined CDC and bank portions)
Best for: Dermatology practice acquisitions that include significant real estate, such as purchasing the clinic building alongside the business — the 504 program provides long-term fixed-rate financing for owner-occupied commercial real estate tied to the practice
Eligibility Requirements
- The acquiring entity must be a for-profit business operating in the United States, with the buyer demonstrating sufficient management experience in healthcare operations or clinical practice ownership
- The dermatology practice being acquired must have a documented history of positive cash flow, typically demonstrated through 3 years of tax returns and financial statements showing EBITDA sufficient to service the proposed debt
- The buyer must inject a minimum of 10% equity as a down payment, though lenders may require 15–20% for practices with elevated key-person risk, such as single-physician operations where the selling dermatologist owns 80%+ of revenue
- The total loan amount including all project costs must not exceed $5 million under the standard SBA 7(a) program, making it appropriate for most lower middle market dermatology acquisitions in the $1M–$5M revenue range
- The deal structure must be lender-approvable under healthcare regulations, including proper MSO structuring to comply with state corporate practice of medicine laws — buyers should engage a healthcare M&A attorney before submitting a loan application
- The buyer must not be delinquent on any existing federal debt, must have a clean personal credit profile (typically 680+ FICO), and must demonstrate the ability to personally guarantee the SBA loan as required by the program
Step-by-Step Process
Identify and Evaluate a Target Dermatology Practice
Source acquisition targets through healthcare business brokers, physician retirement networks, or direct outreach to independent dermatology practices in your target geography. Evaluate practices based on key acquisition criteria: minimum $1M EBITDA preferred, 2+ licensed providers, diversified payer mix with less than 40% Medicare dependency, strong cosmetic revenue contribution, and clean malpractice history. Request a Confidential Information Memorandum (CIM) and preliminary financial statements before engaging further.
Engage a Healthcare M&A Attorney and CPA
Before submitting a Letter of Intent, engage a healthcare M&A attorney experienced in your state's corporate practice of medicine laws. They will advise on whether an MSO structure is required, how to legally structure the acquisition entity, and what provisions must appear in physician employment agreements. A CPA with healthcare practice experience should recast the seller's financials to identify personal expenses, normalize EBITDA, and separate cosmetic from medical revenue streams — both critical inputs for SBA loan underwriting.
Submit a Letter of Intent (LOI) and Agree on Deal Terms
Submit a non-binding LOI outlining the proposed purchase price, deal structure (asset purchase with MSO or stock purchase with equity rollover), down payment, seller note terms, and seller transition period. For dermatology acquisitions, a 12–24 month post-close transition with the selling physician is standard and often required by SBA lenders to mitigate key-person risk. Agree on earnout provisions if a portion of the purchase price is tied to post-close EBITDA performance.
Select an SBA Lender with Healthcare Lending Experience
Apply to SBA Preferred Lender Program (PLP) banks with documented experience financing physician practice acquisitions and MSO deal structures. Provide the lender with 3 years of practice tax returns and P&Ls, the buyer's personal financial statement and resume, a business plan with pro forma financials, and the draft purchase agreement. Avoid general commercial lenders unfamiliar with CPOM regulations — they will slow the process significantly or decline deals they don't understand.
Complete SBA Underwriting and Obtain Loan Commitment
The lender will conduct a formal credit analysis including a practice valuation (typically using an independent third-party appraisal), DSCR analysis based on normalized EBITDA, and a review of payer contracts, billing history, and malpractice claims. SBA underwriting for a dermatology practice typically takes 30–60 days. The lender will issue a Commitment Letter outlining final loan terms, conditions precedent to closing, and required documentation.
Conduct Full Due Diligence
Simultaneously with SBA underwriting, conduct comprehensive due diligence. For dermatology acquisitions, this must include: review of all physician and mid-level provider employment agreements and non-compete enforceability; audit of payer contracts, reimbursement rates, and revenue cycle management; malpractice claims history and tail coverage obligations; patient volume trends segmented by medical versus cosmetic appointments; state licensure, DEA registrations, and Medicare provider enrollment status; and facility lease terms including assignment consent from the landlord.
Close the Transaction
Finalize the purchase agreement, MSO agreement, physician employment agreements, and any earnout documentation with your healthcare attorney. The SBA lender will coordinate the closing and fund the loan. Seller proceeds are disbursed, the seller note is executed, and the transition period begins. Immediately file for Medicare and Medicaid provider enrollment under the new ownership entity — this process can take 60–90 days and should be initiated before closing to avoid billing interruptions.
Common Mistakes
- ✗Applying to a general SBA lender without healthcare deal experience, resulting in delays or a declined loan when the underwriter is unfamiliar with MSO structures, corporate practice of medicine laws, or how to value medical goodwill in a dermatology practice
- ✗Failing to separate cosmetic from medical revenue in the financial presentation to the lender — cosmetic revenue carries higher margins and is cash-pay, which significantly improves DSCR projections, and not highlighting this distinction leaves money on the table during underwriting
- ✗Underestimating key-person risk in a single-physician practice and not negotiating a robust 12–24 month transition agreement with the seller before closing, which can trigger higher down payment requirements or outright loan denial from lenders concerned about revenue continuity
- ✗Neglecting to initiate Medicare and Medicaid provider enrollment re-credentialing before closing, leading to billing interruptions of 60–90 days post-close that create serious cash flow problems during the critical early ownership period
- ✗Overlooking tail coverage obligations for claims-made malpractice policies held by the selling physician — failing to clarify who pays for tail coverage (often a six-figure expense) before closing can derail a deal or create unexpected post-close liability for the buyer
Lender Tips
- Prioritize SBA Preferred Lender Program (PLP) banks with dedicated healthcare lending divisions — look for lenders who have closed dermatology or physician practice deals in the past 24 months and can provide references from similar transactions
- Present a clean, lender-ready financial package that includes 3 years of practice tax returns, a recast EBITDA schedule with add-backs clearly documented, a cosmetic-versus-medical revenue breakdown with margin analysis, and a pro forma showing projected debt service coverage of at least 1.25x post-acquisition
- Include a detailed seller transition plan in your loan package — lenders weight this heavily for dermatology acquisitions, and a documented 18–24 month employment agreement with the selling physician materially reduces perceived key-person risk and can improve loan terms
- Be transparent about the MSO structure from the first lender conversation — provide a one-page summary of how the MSO and PC (professional corporation) will be structured, who holds clinical licensure, and how cash flows from the PC to the MSO, so the lender's underwriter doesn't encounter surprises mid-process
- Demonstrate your clinical or operational qualifications upfront — lenders want to see that the buyer has relevant experience managing or working in a healthcare practice, so include a professional biography, any relevant certifications, and references from other healthcare professionals or operators you have worked with
Find SBA-Ready Dermatology Practice Businesses
Pre-screened acquisition targets with verified financials — free to join.
SBA Loan Calculator
Estimate your monthly payment for a Dermatology Practice acquisition
Standard for acquisitions
Powered by Deal Flow OS
dealflow-os.com · Free M&A tools for every stage of the deal
Frequently Asked Questions
Can a non-physician use an SBA loan to acquire a dermatology practice?
Yes, but with important caveats. Many states have corporate practice of medicine (CPOM) laws that prohibit non-physicians from directly owning or operating a medical practice. In these states, a non-physician buyer must use a Management Services Organization (MSO) structure, where a non-clinical management company (which the buyer owns) contracts with a physician-owned professional corporation (PC) to provide all non-clinical services — billing, staffing, facilities, and administration — in exchange for a management fee. SBA lenders can finance this structure, but they must understand it thoroughly. Engaging a healthcare M&A attorney to structure the MSO and a lender with healthcare lending experience is essential for non-physician buyers.
How do SBA lenders value a dermatology practice for loan underwriting purposes?
SBA lenders typically require an independent third-party business appraisal for any acquisition involving goodwill. For dermatology practices, appraisers use a combination of income-based approaches (capitalizing normalized EBITDA) and market comparables. Dermatology practices in the lower middle market typically trade at 4x–7x EBITDA depending on size, provider count, payer mix, and cosmetic revenue contribution. Practices with strong cosmetic revenue (Botox, fillers, laser), multiple licensed providers, and minimal key-person risk command multiples at the higher end of that range. The lender's appraisal must support the purchase price for the loan to be approved — if the appraised value comes in below the agreed purchase price, the buyer must either renegotiate or cover the gap with additional equity.
How long does it take to get SBA financing approved for a dermatology practice acquisition?
From the time a complete loan application is submitted to a Preferred Lender Program (PLP) bank, SBA loan approval typically takes 30–60 days for a dermatology practice acquisition. Total time from signed LOI to closing — including due diligence, underwriting, legal documentation, and closing coordination — is typically 90–120 days. Deals involving complex MSO structures, multi-physician practices, or payer contract renegotiations may take longer. Buyers should plan for a 4–5 month timeline from LOI to close and communicate that expectation to the seller upfront to avoid deal fatigue.
What role does cosmetic revenue play in SBA loan eligibility for a dermatology practice?
Cosmetic revenue is a significant positive factor in SBA underwriting for dermatology acquisitions. Procedures like Botox, dermal fillers, laser hair removal, and chemical peels are cash-pay services with high margins and no reimbursement risk from insurance payers. Lenders view this revenue as more predictable and higher-quality from a cash flow standpoint than insurance-billed medical dermatology, which is subject to reimbursement rate changes and denial risk. A practice with 30–40% of revenue from cosmetic services will typically show a stronger DSCR and may qualify for better loan terms. Buyers should ensure cosmetic and medical revenue are clearly segmented in the financial package submitted to lenders.
What is a seller note and how does it work in a dermatology practice SBA acquisition?
A seller note is a portion of the purchase price — typically 10–15% — that the seller agrees to finance directly, meaning the buyer repays the seller over time rather than paying that amount in cash at closing. In SBA-financed dermatology acquisitions, seller notes serve two purposes: they reduce the buyer's required cash injection and signal the seller's confidence in the practice's continued performance post-sale, which lenders view positively. SBA rules require that seller notes be on full standby for the first 24 months of the SBA loan, meaning the seller cannot receive principal or interest payments during that period. This must be clearly documented in the loan agreement and purchase contract. A typical structure might be: 10% buyer equity injection, 10–15% seller note on standby, and 75–80% SBA 7(a) loan financing.
What due diligence items are most critical for lenders reviewing a dermatology practice acquisition?
SBA lenders focused on dermatology acquisitions will scrutinize several items beyond standard financial statements. Payer contract documentation — including reimbursement rates, contract terms, and renewal provisions — is critical because revenue sustainability depends on it. Physician employment agreements and non-compete clauses are reviewed to assess key-person risk and ensure the selling dermatologist is contractually committed to a transition period. Malpractice claims history and insurance policy type (occurrence vs. claims-made with tail coverage) are reviewed for liability exposure. Patient volume trends segmented by medical and cosmetic appointments help validate revenue sustainability. Finally, state licensure compliance, Medicare/Medicaid enrollment status, and corporate practice of medicine compliance documentation must be clean and current before a lender will commit to funding.
More Dermatology Practice Guides
More SBA Loan Guides
Start Finding Dermatology Practice Deals Today — Free to Join
Find SBA-eligible targets, score seller motivation, and get AI-written outreach in one platform.
Create your free accountNo credit card required